{"protocolSection":{"identificationModule":{"nctId":"NCT00077805","orgStudyIdInfo":{"id":"XRP4563H_4001"},"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)","officialTitle":"An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2011-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-08"},"primaryCompletionDateStruct":{"date":"2006-07","type":"ACTUAL"},"studyFirstSubmitDate":"2004-02-12","studyFirstSubmitQcDate":"2004-02-13","studyFirstPostDateStruct":{"date":"2004-02-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-01-10","lastUpdatePostDateStruct":{"date":"2011-01-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Medical Affairs Study Director","oldOrganization":"sanofi-aventis"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"Primary objective:\n\n* To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.\n\nSecondary objectives:\n\n* To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization\n* To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization\n* To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke"},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Enoxaparin sodium"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cumulative occurrence of VTE events (deep-vein thrombosis, pulmonary embolism)","timeFrame":"10 ± 4 days following acute ischemic stroke"}],"secondaryOutcomes":[{"measure":"cumulative VTE events","timeFrame":"at 30-day, 60-day and 90-day"},{"measure":"stroke recurrence, stroke progression, National Institute of Health Stroke Scale (NIHSS) scores","timeFrame":"during treatment and follow-up periods"},{"measure":"Modified Rankin Scale (MRS) scores","timeFrame":"at 30-day and 90-day follow-up"},{"measure":"major & minor hemorrhages","timeFrame":"from the inform consent signed up to the end of the study"},{"measure":"Treatment emergent adverse events (TEAE), serious adverse events (SAE), all-cause mortality","timeFrame":"from the inform consent signed up to the end of the study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke\n* Onset of symptoms of qualifying stroke within 48 hours prior to randomization. In patients receiving thrombolytic therapy for the acute stroke, such as tissue-type plasminogen activator (tPA), administration of study drug may not start until at least 24 hours after completion of thrombolytic therapy\n* Significant motor impairment of the leg, as indicated by a NIHSS score ≥2 on item 6\n* Inability to walk without assistance\n\nExclusion criteria:\n\n* Females who are pregnant, breast-feeding, or of childbearing potential and not using medically acceptable and effective contraception\n* Clinical evidence of VTE at screening\n* Any evidence of active bleeding on the basis of clinical judgment\n* Prior history of intracranial hemorrhage (including that at screening)\n* Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours\n* Thrombolytic therapy (e.g., tPA) or intra-arterial thrombolytic therapy within the preceding 24 hours.Thrombolytic therapy is permitted for treatment of the acute stroke but must have been completed 24 hours prior to randomization.\n* Comatose at screening (NIHSS score ≥2 on item 1a)\n* Known or suspected cerebral aneurysm or arteriovenous malformation\n* Confirmed malignancy that may pose an increased risk for bleeding or otherwise compromise follow-up or outcome assessment (e.g., lung cancer)\n* Impaired hemostasis, i.e., known or suspected coagulopathy (acquired or inherited); baseline platelet count \\<100,000/mm3; aPTT 1.5 X the laboratory upper limit of normal; or international normalized ratio(INR) \\>1.5\n* Major surgery or recent major trauma within the previous 3 months\n* Anticipated need for full-dose treatment with therapeutic levels of an anticoagulant (LMWH, UFH, oral anticoagulant), e.g., for cardiogenic source of embolism or dissection\n* Treatment with a LMWH or UFH at prophylactic dose for more than 48 hours prior to randomization(patients receiving LMWH or UFH less than 48 hours prior to randomization may be randomized)\n* Allergy to heparin or enoxaparin sodium, or known hypersensitivity to heparin, enoxaparin, or pork products\n* History of heparin or enoxaparin induced thrombocytopenia and/or thrombosis (heparin-induced thrombocytopenia \\[HIT\\], heparin-associated thrombocytopenia \\[HAT\\], or heparin-induced thrombotic thrombocytopenia syndrome \\[HITTS\\])\n* History of hypersensitivity to iodinated contrast media and/or iodine\n* Bacterial endocarditis\n* Prosthetic heart valve\n* Known or suspected severe anemia (Hg \\<10.0 g/dL)\n* Uncontrolled arterial hypertension (systolic blood pressure \\[BP\\] \\>180 mmHg or diastolic BP \\>100 mmHg) at the time of randomization or clinical hypertensive urgency\n* Any other clinically relevant serious diseases, including severe liver disease or renal failure \\[creatinine clearance \\<30 mL/min on at least two occasions\\].\n* Treatment with other investigational agents or devices within the previous 30 days, planned use of other investigational drugs or devices, or previous enrollment in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Luc Sagnard","affiliation":"Sanofi","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Sanofi-Aventis","city":"Bridgewater","state":"New Jersey","country":"United States","geoPoint":{"lat":40.60079,"lon":-74.64815}},{"facility":"Sanofi-Aventis","city":"North Ryde","country":"Australia","geoPoint":{"lat":-33.79677,"lon":151.12436}},{"facility":"Sanofi-Aventis","city":"Vienna","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Sanofi-Aventis","city":"Sao Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Sanofi-Aventis","city":"Laval","country":"Canada","geoPoint":{"lat":45.56995,"lon":-73.692}},{"facility":"Sanofi-Aventis","city":"Bogota","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Sanofi-Aventis","city":"Prague","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Sanofi-Aventis","city":"Mumbai","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Sanofi-Aventis","city":"Natanya","country":"Israel"},{"facility":"Sanofi-Aventis","city":"Milan","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Sanofi-Aventis","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Sanofi-Aventis","city":"Mexico","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Sanofi-Aventis","city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Sanofi-Aventis","city":"Johannesburg","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Sanofi-Aventis","city":"Istanbul","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}}]},"referencesModule":{"references":[{"pmid":"19696423","type":"RESULT","citation":"Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF; PREVAIL Investigators. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke. 2009 Nov;40(11):3532-40. doi: 10.1161/STROKEAHA.109.555003. Epub 2009 Aug 20."},{"pmid":"17448820","type":"RESULT","citation":"Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007 Apr 21;369(9570):1347-1355. doi: 10.1016/S0140-6736(07)60633-3."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Greece"]},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000013923","term":"Thromboembolism"},{"id":"D000054556","term":"Venous Thromboembolism"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M4804","name":"Body Weight","relevance":"LOW"},{"id":"M16372","name":"Thromboembolism","asFound":"Thromboembolism","relevance":"HIGH"},{"id":"M27470","name":"Venous Thromboembolism","asFound":"Venous Thromboembolism","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000017984","term":"Enoxaparin"},{"id":"C000711671","term":"Enoxaparin sodium"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M19842","name":"Enoxaparin","asFound":"Professional","relevance":"HIGH"},{"id":"M9269","name":"Heparin","relevance":"LOW"},{"id":"M136959","name":"Enoxaparin sodium","asFound":"Controlled ventilation","relevance":"HIGH"},{"id":"M9271","name":"Heparin, Low-Molecular-Weight","relevance":"LOW"},{"id":"M19843","name":"Dalteparin","relevance":"LOW"},{"id":"M45780","name":"Calcium heparin","relevance":"LOW"},{"id":"M1943","name":"Tinzaparin","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}